Ann Janssens

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 583 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan et al. · The Lancet Oncology · 2015 · 408 citations

Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia, Medicine +9

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Peter Hillmen, Tadeusz Robak, Ann Janssens et al. · The Lancet · 2015 · 337 citations

Hematological Malignancy, Immunohematology, Complement 1 +13

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin et al. · Leukemia · 2020 · 271 citations · Full text